The present study analyzed the expression and clinical role of the
protein of regenerating liver (PRL)
phosphatase family in ovarian
carcinoma. PRL1-3
mRNA expression was studied in 184
tumors (100 effusions, 57 primary
carcinomas, 27 solid
metastases) using RT-PCR. PRL-3
protein expression was analyzed in 157
tumors by Western blotting. PRL-1
mRNA levels were significantly higher in effusions compared to solid
tumors (p < 0.001), and both PRL-1 and PRL-2 were overexpressed in pleural compared to peritoneal effusions (p = 0.001). PRL-3
protein expression was significantly higher in primary diagnosis pre-
chemotherapy compared to post-
chemotherapy disease recurrence effusions (p = 0.003). PRL-1
mRNA expression in effusions correlated with longer overall survival (p = 0.032), and higher levels of both PRL-1 and PRL-2
mRNA correlated with longer overall survival for patients with pre-
chemotherapy effusions (p = 0.022 and p = 0.02, respectively). Analysis of the effect of
laminin on PRL-3 expression in ovarian
carcinoma cells in vitro showed dose-dependent PRL-3 expression in response to exogenous
laminin, mediated by
Phospholipase D. In contrast to previous studies associating PRL-3 with poor outcome, our data show that PRL-3 expression has no clinical role in ovarian
carcinoma, whereas PRL-1 and PRL-2 expression is associated with longer survival, suggesting that PRL
phosphatases may be markers of improved outcome in this
cancer.